HC Wainwright Has Optimistic Outlook of BCRX Q2 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – HC Wainwright increased their Q2 2025 EPS estimates for shares of BioCryst Pharmaceuticals in a research note issued on Tuesday, May 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $0.10 per share for the quarter, up from their prior estimate of ($0.01). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at $0.56 EPS, FY2027 earnings at $0.88 EPS and FY2028 earnings at $1.29 EPS.

Other research analysts have also issued reports about the company. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an “overweight” rating and a $20.00 price objective for the company. Barclays raised their price objective on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Evercore ISI upped their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. JPMorgan Chase & Co. lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $13.00 price objective (up from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $16.56.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $10.08 on Thursday. The company has a market capitalization of $2.11 billion, a P/E ratio of -16.52 and a beta of 1.08. The company has a 50 day simple moving average of $7.81 and a 200-day simple moving average of $7.86. BioCryst Pharmaceuticals has a 1 year low of $5.04 and a 1 year high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.28 EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BCRX. GSA Capital Partners LLP boosted its position in shares of BioCryst Pharmaceuticals by 69.3% during the 1st quarter. GSA Capital Partners LLP now owns 278,552 shares of the biotechnology company’s stock worth $2,089,000 after purchasing an additional 114,068 shares in the last quarter. Federated Hermes Inc. boosted its holdings in BioCryst Pharmaceuticals by 10.1% during the first quarter. Federated Hermes Inc. now owns 184,904 shares of the biotechnology company’s stock worth $1,387,000 after buying an additional 16,947 shares in the last quarter. Mackenzie Financial Corp grew its position in BioCryst Pharmaceuticals by 37.3% during the first quarter. Mackenzie Financial Corp now owns 116,258 shares of the biotechnology company’s stock worth $872,000 after buying an additional 31,596 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in BioCryst Pharmaceuticals in the first quarter valued at about $125,000. Finally, Y Intercept Hong Kong Ltd increased its holdings in BioCryst Pharmaceuticals by 106.7% in the first quarter. Y Intercept Hong Kong Ltd now owns 141,865 shares of the biotechnology company’s stock valued at $1,064,000 after buying an additional 73,242 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.